Epidermal Growth Factor Receptor-stimulated Activation of Phospholipase Cγ-1 Promotes Invasion of Head and Neck Squamous Cell Carcinoma

Sufi Mary Thomas, Francesca M. Coppelli, Alan Wells, William E. Gooding, John Song, Jareer Kassis, Stephanie D. Drenning, and Jennifer Rubin Grandis

Departments of Otolaryngology [S. M. T., F. M. C., J. S., S. D. D., J. R. G.], Pharmacology [J. R. G.], Pathology [A. W., J. K.], and Biostatistics [W. E. G.], University of Pittsburgh, University of Pittsburgh Cancer Institute, and Pittsburgh Veterans’ Administration Medical Center [A. W., J. K.], Pittsburgh, Pennsylvania 15213

ABSTRACT

Lymph node metastasis and local invasion of head and neck squamous cell carcinoma (HNSCC) is associated with a poor prognosis. However, little is known about the factors governing tumor cell invasion in HNSCC. Phospholipase Cγ-1 (PLCγ-1) contributes to tumor cell invasion in experimental systems when activated by the epidermal growth factor receptor (EGFR). We hypothesized that EGFR overexpression in HNSCC mediates invasion via PLCγ-1. On EGFR ligand stimulation, phosphorylation of PLCγ-1 increased in all of the HNSCC cell lines tested (4 of 4). In the presence of EGFR-specific tyrosine kinase inhibitor (PD153035) or an anti-EGFR antibody (C225), PLCγ-1 activation was abrogated indicating that PLCγ-1 was downstream of EGFR. Blocking cellular PLC with an inhibitor (U73122) reduced inositol phosphate turnover in all of the HNSCC cell lines examined, and treatment with the PLC inhibitor or antisense oligonucleotides targeting PLCγ-1 significantly reduced in vitro invasiveness of HNSCC cell lines through Matrigel. To determine the clinical relevance of these findings, we compared levels of PLCγ-1 in tumor and paired normal tissue from 33 patients with HNSCC. PLCγ-1 levels were significantly higher (P < 0.0001) in the tumors compared with the normal mucosa of HNSCC patients. Levels of activated PLCγ-1 were analyzed in 20 patients. Tumors expressed higher levels of phosphorylated PLCγ-1 compared with normal adjacent mucosa (P = 0.05). Thus, PLCγ-1 may mediate invasion and metastasis downstream of EGFR in HNSCC.

INTRODUCTION

Nearly 50% of patients with HNSCC1 present with cervical lymph node metastases (1). Invasion of the tumor into the neck viscera is a primary cause of morbidity and mortality in this cancer. The mechanisms that govern tumor cell invasion in HNSCC are incompletely understood. Elucidation of the molecular events that mediate invasion is required to improve therapeutic approaches and, hence, survival. More than 95% of HNSCC tumors express elevated levels of the EGFR (2, 3). We have shown previously that increased EGFR expression in HNSCC tumors correlates with reduced survival and an increased incidence of lymph node metastasis (4). An established oncogene, EGFR mediates cellular motility, proliferation, and prevents apoptosis in HNSCC cells via activation of a number of downstream signaling pathways. Activation of these pathways by EGFR is necessary for tumor progression (5). However, to rationally disrupt these events, an increased understanding of EGFR signaling is required to elucidate its biological role in cancers including HNSCC.

Several signaling pathways downstream of EGFR have been reported in HNSCC including the MAPK, phosphatidylinositol 3’-kinase, and STATs (6). Several lines of evidence suggest a redundancy among EGFR signaling pathways (7), whereas others have reported modulation of a specific phenotype when one pathway is specifically targeted. In HNSCC cells, EGFR-stimulated MAPK activation induced proliferation but not invasion (8). The phosphatidylinositol 3’-kinase pathway has been implicated in mediating anti-apoptotic functions and conferring radiation-resistance in HNSCC cells (9). We have shown previously that EGFR-mediated STAT3 activation is required for cell growth and survival in vitro (10). Additional evidence suggests that constitutively activated STAT3 in HNSCC tumors results in uncontrolled cell growth by an antiapoptotic mechanism (11). Phosphoinositide biphosphorylation downstream from PLCγ activation has not been studied previously in HNSCC.

The present study was undertaken to test the hypothesis that EGFR stimulation of PLCγ-1 mediates cell invasion in HNSCC. We examined PLCγ-1 expression and activation in a series of HNSCC cell lines and patient tissues. Blockade of EGFR abrogated PLCγ-1 levels suggesting that PLCγ-1 activation in HNSCC cells was primarily because of EGFR stimulation. Abrogation of PLCγ-1 decreased HNSCC cell invasion in vitro without affecting cell proliferation. In vivo, PLCγ-1 was expressed and phosphorylated at higher levels in tumor tissue compared with normal adjacent mucosa. These results indicate that EGFR-mediated PLCγ-1 activation modulates invasion of HNSCC cells and may contribute to tumorigenesis.

MATERIALS AND METHODS

Cell Lines and Tissues. Cell lines derived from HNSCC were maintained in DMEM with 10% FBS (Life Technologies, Inc., Grand Island, NY). The OSC-19 cell line was cultured in Eagle’s MEM containing 10% FBS and nonessential amino acids (0.1 mM). Cell lines OSC-19 (12) and PCI-15b were derived from metastatic lymph nodes (13). UM-22a was derived from a SCC of the buccal mucosal (14). UPCI-SCC32, derived from the retromolar trigone, is a generous gift from Dr. Susanne M. Gollin (University of Pittsburgh, Pittsburgh, PA). A431 is a well-characterized vulvar SCC known to over-express EGFR and was used as a positive control. Patient tissues used in the study were obtained from patients undergoing surgery at the University of Pittsburgh Medical Center. Primary HNSCC and normal adjacent mucosa (~5 cm away from tumor site) were harvested under the auspices of an Institutional Review Board-approved protocol. Signed informed consent was obtained from each subject.

Reagents. For in vitro cell stimulation, recombinant human EGF (Sigma Chemical Co., St. Louis, MO) was used. U73122 (BioMol, Plymouth Meeting, PA) was used to block PLC activity. An inactive analogues of U73122, U73134 (BioMol), was used as a negative control. Specific EGFR tyrosine kinase inhibitor PD153035 was obtained from Calbiochem-Novabiochem Corporation (San Diego, CA). The EGFR blocking antibody C225 was obtained from Imclone Systems Incorporated (New York, NY). Antibodies used included mouse monoclonal anti-PLCγ-1 (Upstate Biotechnology, Lake Placid, NY), anti-phospho-PLCγ-1 (Cell Signaling Technologies, Beverly, MA), and β-actin (Calbiochem-Novabiochem Corporation). Antisense and scrambled PLCγ-1 oligonucleotides were obtained from MWG Biotech (High Point, NC). The PLCγ-1 antisense oligonucleotide (5’AGGGGACGCGGCGCCCGCCAT3’) is a 21-mer fragment directed against the translation initiation site of human

Received 2/12/03; revised 5/20/03; accepted 6/11/03.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by NIH Grant 5RO1CA73708 (to J. R. G.), a Veterans Administration Merit Award (to A. W.) and a Lung Specialized Program of Research Excellence postdoctoral fellowship (to S. M. T.).

2 To whom requests for reprints should be addressed, at Department of Otolaryngology, The Eye and Ear Institute Building, Suite 500, 200 Lothrop Street, Pittsburgh, PA 15213. Phone: (412) 647-5280; Fax: (412) 647-2080; E-mail: jgrandis@pitt.edu.

3 The abbreviations used are: HNSCC, head and neck squamous cell carcinoma; EGF, epidermal growth factor receptor; MAPK, mitogen-activated protein kinase; STAT, signal transducers and activators of transcription; PLCγ, phospholipase Cγ; FBS, fetal bovine serum; SCC, squamous cell carcinoma; EGFR, epidermal growth factor; IP, inositol phosphate; MMP, matrix metalloproteinase.
PLCγ-1 (derived from Ref. 15). A control scrambled oligonucleotide sequence of the antisense sequence to PLCγ-1 (5′ ATCCGGGTTGGCGCGGCACAG3′) was also used in the study.

Effect of PLC Inhibition on Cellular Proliferation. The cytotoxic effects of the PLC inhibitor U73122 and antisense PLCγ-1 oligonucleotides were determined by incubating HNSCC cells in increasing concentrations of reagents for 2–4 days. Cells were plated in growth medium (MEM + 10% FCS + 1% nonessential amino acids) in triplicate wells at a density of 2 × 10^4 cells/well in 24-well plates. After 24 h, the medium was replaced with growth medium containing either the PLC inhibitor U73122 or vehicle control (chloroform). For studies with oligonucleotides, medium was replaced with serum-free medium containing the respective oligonucleotides. At a predetermined end point cells were trypsinized and counted on a hemocytometer.

Immunohostting. Briefly, 80–90% confluent cells were serum starved for 48 h. Cells were then subjected to either 3 μg U73122 or U73343 for 25 min, 200 nm PD153035 or 7 μM C225 for 2 h followed by stimulation with 10 ng/ml of recombinant human EGF for 5 min. After treatment, cells were harvested in lysis buffer (10 mM Tris HCl (pH 7.6), 50 mM Na3PO4, 50 mM NaF, 1 mM NaVO4, 1% Triton X-100 and 1× protease inhibitor mixture tablet that included a broad spectrum potent inhibitor of protein tyrosine phosphatases (Roche, Germany)). Lysates were sonicated for 3 s and centrifuged at 4°C, 14,000 rpm for 5 min. The supernatant was collected for protein quantitation using the Bio-Rad protein assay dye reagent (Bio-Rad Laboratories, Hercules, CA) and BSA of known concentration as the standard. Fifty μg of protein was size-fractionated through an 8% SDS-PAGE gel and immunoblotted with anti-PLCγ1 antibody (Cell Signaling Technologies) followed by anti-PLCγ1 antibody (Upstate Biotechnology).

Frozen HNSCC tumor and normal tissue samples were finely minced and suspended in 1 ml of lysis buffer (1% NP40, 0.1 M phenylmethylsulfonyl fluoride, and 1 μg/ml leupeptin and apro tinin). The cell debris was pelleted and the supernatant aliquoted, protein concentration estimated, and the proteins were size-fractionated on an 8% SDS-PAGE gel as mentioned before. Paired samples for tumor and normal tissue were always run next to each other on the same gel. Twenty μg of A431 protein extract was loaded on every gel as a positive control and normalization standard. Samples were electrophoresed along with a Bio-Rad molecular weight marker (Bio-Rad). The proteins were transferred to a nitrocellulose membrane in a semidy dry transfer apparatus (Bio-Rad). Western blots were probed with anti-PLCγ1, anti-phospho-PLCγ1, or anti-β-actin antibody (Oncogene Research Products), and the signals were obtained on autoradiograms after enhanced chemiluminescent detection (Amersham ECL kit). Signals were quantified on a Molecular Dynamics Personal Densitometer SI and ImageQuant software (Image Products International, Chantilly, VA). Values obtained from PLCγ1 and pPLCγ1 quantification were normalized to β-actin levels as well as A431 levels. The ratio of the tumorous levels of PLCγ1 and phospho-PLCγ1 levels were calculated.

In Vitro Invasion of HNSCC Cells. Cell invasiveness was evaluated in vitro using Matrigel-coated semipermeable modified Boyden inserts with a pore size of 8 μm. Cells were serum starved for 48 h to minimize the effects of growth factors in the serum and signaling from secreted autocrine ligands. Cells were then stimulated with recombinant EGF (10 ng/ml for 5 min). Total cellular protein was harvested and fractionated on a SDS-PAGE gel. Western blotting was performed with anti-phospho-PLCγ1 followed by anti-PLCγ1 antibody to demonstrate equal loading. In all four of the cell lines tested, the EGFR ligand increased phosphorylation of PLCγ1 compared with corresponding unstimulated cells (Fig. 1B). These findings suggest that EGFR ligand stimulation induces phosphorylation and, hence, activation of PLCγ1 in HNSCC cells.

RESULTS

EGFR Stimulation Increases PLCγ1 Activation in HNSCC Cells. Expression and activation of PLCγ1 has not been studied previously in HNSCC cells. Four HNSCC cell lines were screened for expression of PLCγ1. All four of the cell lines were found to express basal levels of PLCγ1 (Fig. 1A). Phosphorylation of PLCγ1 by EGFR tyrosine kinase results in activation of PLCγ1. The ability of EGFR ligand, EGF, to induce PLCγ1 phosphorylation was tested. HNSCC cells were serum starved for 48 h to minimize the effects of growth factors in the serum and signaling from secreted autocrine ligands. Cells were then stimulated with recombinant EGF (10 ng/ml for 5 min). Total cellular protein was harvested and fractionated on a 10% SDS/PAGE gel. Western blotting was performed with anti-phospho-PLCγ1 followed by anti-PLCγ1 antibody to demonstrate equal loading. In all four of the cell lines tested, the EGFR ligand increased phosphorylation of PLCγ1 compared with corresponding unstimulated cells (Fig. 1B). These findings suggest that EGFR ligand stimulation induces phosphorylation and, hence, activation of PLCγ1 in HNSCC cells.

Fig. 1. EGFR stimulation activates PLCγ1 in HNSCC cells. A. PLCγ1 levels in HNSCC cell lines. Four representative HNSCC cell lines were analyzed for PLCγ1 expression by Western blotting. The same membrane was probed for β-actin to demonstrate equal loading. B. four representative HNSCC cell lines were analyzed for PLCγ1 activation. Cell lysates from representative HNSCC cell lines (UPCI: SCCC2, OSC-19, PCI-13b, and UM-22a) were treated with recombinant EGF (10 ng/ml for 5 min) followed by immunoblotting with anti-phospho-PLCγ1 antibody. The same blot was probed with anti-PLCγ1 and β-actin antibodies to show equal loading of protein in all lanes. EGFR ligand stimulation results in increased activation of pPLCγ1 (top panel), whereas total levels of PLCγ1 (bottom panel) remain unchanged.

5630
Blockade of EGFR and PLC Abrogates the Activation of PLCγ-1. 

PLCγ-1 can be stimulated after activation of several growth factor receptors including EGFR. To determine whether activation of PLCγ-1 was mediated via an EGFR signaling pathway, HNSCC cells were treated with an EGFR-specific tyrosine kinase inhibitor (PD153035) at a dose reported previously to block EGFR phosphorylation in HNSCC cells (17). A representative HNSCC cell line (OSC-19) was pretreated for 2 h with either EGFR inhibitor PD153035 (200 nM) or anti-EGFR antibody C225 (7 μg/ml), or for 25 min with PLC inhibitor U73122 or the inactive analogue U73343 (3 μM). Pretreatment was followed by EGF stimulation (10 ng/ml for 5 min). Protein extracts were fractionated on a SDS-PAGE gel. Immunoblots were probed with anti-phospho-PLCγ-1 antibody and PLCγ-1 antibody to demonstrate equal loading. Activation of PLCγ-1 was reduced by EGFR or PLC inhibition by more than 90% (Fig. 2, A and B). These results indicate that EGFR activation stimulates PLCγ-1 phosphorylation in HNSCC cells.

Inhibition of PLCγ-1 Signaling Reduces Cell Invasion in Vitro.

To determine whether PLC blockade abrogated HNSCC cell invasion in vitro, six HNSCC cell lines were plated in duplicate in transwell chambers at 2 × 10⁴ cells/well with either EGF or the PLC inhibitor in the upper and lower chambers. After 24 h the cells on the lower side of the chamber were fixed and stained. The number of cells that invaded the Matrigel coated transwell chamber was counted using a light field inverted microscope. An average of four fields of cells counted under 400× magnification was determined. We found that

![Fig. 2. EGFR mediates activation of PLCγ-1 in HNSCC cells.](image)

A representative HNSCC cell line (OSC-19) was pretreated for 2 h with an EGFR-specific inhibitor PD153035 (200 nM) or a PLC inhibitor U73122 (3 μM for 25 min) and/or treated with EGF (10 ng/ml for 5 min). Cell lysates were size fractionated on a SDS-PAGE gel and immunoblotted with anti-phospho-PLCγ-1 antibody. The same blot was probed for PLCγ-1 to show equal loading of protein in all lanes. Densitometric analysis was carried out and gels were normalized to values of corresponding PLCγ-1 levels. Bars, ±SE from two separate experiments.

B, a representative HNSCC cell line (OSC-19) was pretreated for 2 h with anti-EGFR antibody C225 (7 μg/ml) and/or treated with EGF (10 ng/ml for 5 min). Cell lysates were size fractionated on a SDS-PAGE gel and immunoblotted with anti-phospho-PLCγ-1 antibody. The same blot was probed for PLCγ-1 to show equal loading of protein in all lanes. Densitometric analysis was carried out and gels were normalized to values of corresponding PLCγ-1 levels. Bars, ±SE from two separate experiments.

![Fig. 3. PLC inhibition decreases invasion of representative HNSCC cell lines in vitro.](image)

A, the percent invasion of HNSCC cells (UPCI:SCC32, OSC-19, PCI-15b, and UM-22a) through Matrigel-coated transwell chambers was calculated relative to the control Bars, ±SE of duplicate samples. There was a reduction in the number of invading cells in the presence of the PLC inhibitor U73122 as compared with the untreated control. B, IP turnover in representative HNSCC cell lines (OSC-19, PCI-15b, and UM-22a). PLC activity was measured as the production of IPs by anion-exchange chromatography. The effect of U73122 (3 μM for 25 min) on IP turnover in EGF-treated (10 ng/ml for 5 min) cells was calculated and normalized to the control (EGF-treated). C, effect of PLC or EGFR inhibition on cell invasion in vitro. A representative HNSCC cell line (OSC-19) was plated in transwell invasion chambers in the presence of either an EGFR inhibitor PD153035 (200 nM) or PLC inhibitor U73122 (3 μM). The percentage invasion was determined by normalizing the number of cells that migrated in the control group. The experiment was repeated three times with similar results.
EGFR MEDIATES INVASION OF HNSCC VIA PLCγ-1 ACTIVATION

A

\[
\text{PLCγ-1} \rightarrow \text{β-Actin}
\]

B

<table>
<thead>
<tr>
<th>Media control</th>
<th>EGF</th>
<th>U73122 + EGF</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antisense PLCγ-1 oligonucleotide</strong> + EGF</td>
<td>Scrambled oligonucleotide + EGF</td>
<td></td>
</tr>
</tbody>
</table>

C

\[
\begin{align*}
\% \text{ Invasion relative to EGF} & \\
\text{Media control} & \pm 10 \% \\
\text{EGF} & \pm 10 \% \\
\text{U73122 + EGF} & \pm 10 \% \\
\text{PLCγ-1 AS oligonucleotide + EGF} & \pm 0 \% \\
\text{Scrambled oligonucleotide + EGF} & \pm 10 \%
\end{align*}
\]

Figure 4. The effect of PLCγ-1 inhibition on invasion in vitro. A, PLCγ-1 expression is decreased by anti-PLCγ-1 antisense oligonucleotides. Cells were treated with 12.5 μM of either antisense PLCγ-1 or scrambled control in the absence of serum for 72 h. Cell lysates were subjected to Western blotting, and the blots were probed with anti-β-actin antibody to demonstrate equal loading. Results from densitometric analysis were plotted as fold change of pPLCγ-1 compared with untreated control. Ratios of pPLCγ-1/β-actin were plotted to account for any variation in loading. B, a representative HNSCC cell line (OSC-19) was plated in transwell invasion chambers in the absence or presence of EGF (10 ng/ml). Duplicate wells were treated in the presence of EGF (10 ng/ml) with either 12.5 μM of PLCγ-1 antisense oligonucleotides, scrambled control oligonucleotides, or 3 μM of PLC inhibitor U73122, or medium alone or EGF alone. After 48 h, noninvading cells inside the wells were wiped off the insert with a cotton-tipped applicator. Invading cells were counted and are expressed as a percentage of total cell number.

To determine whether invasion was mediated by EGFR signaling in vitro, HNSCC cells were plated in Matrigel-coated transwell chambers in the presence of either PLC or EGFR-specific inhibitors (U73122 or PD153035, respectively). After 48 h, the cells that invaded the transwell chamber were fixed, stained, and counted. We found that inhibition of either EGFR or PLC significantly reduced the percentage of cells invading the Matrigel as compared with untreated control wells by >50% (Fig. 3C).

Because U73122 inhibits all of the cellular PLCs, we designed PLCγ-1 antisense oligonucleotides to test the consequence of specific abrogation of PLCγ-1. The antisense oligonucleotide was directed against the ATG start site. HNSCC cells (OSC-19) were plated in invasion chambers at a high density and treated with EGF (10 ng/ml), EGF + U73122 (3 μM), EGF + antisense oligonucleotides against PLCγ-1 (12.5 μM), or EGF + control scrambled oligonucleotides (12.5 μM). Cells were treated for 48 h, fixed, stained, and counted. Immunoblotting demonstrated that the PLCγ-1 antisense oligonucleotides decreased expression of PLCγ-1 protein by 50% (Fig. 4A). Both the PLC inhibitor as well as PLCγ-1 antisense oligonucleotides abrogated in vitro invasion of a representative HNSCC cell line (Fig. 4B). On quantifying the number of invading cells it was found that the number of invading cells in wells with inhibitors was reduced significantly compared with the corresponding controls (P = 0.05 when tested with the Sikak procedure; Fig. 4C).

PLC Inhibition Does Not Abrogate HNSCC Proliferation. We have reported previously that EGFR inhibition abrogates growth of HNSCC cells (17). To determine the effect of PLCγ-1 inhibition on cell proliferation, a representative HNSCC cell line (OSC-19) was treated with 12.5 μM of PLCγ-1 antisense oligonucleotides, scrambled control oligonucleotides, or PLC inhibitor U73122. The cell number in each well was determined at several time points by cell counting using vital dye exclusion. There was no significant difference in cell viability after PLCγ-1 blockade (Fig. 5). The lack of effect of PLCγ-1 inhibition on cell proliferation was corroborated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay as well as flow cytometric analysis (data not shown).

Increased Expression and Activation of PLCγ-1 in Tumors Compared with Corresponding Normal Mucosa from HNSCC Patients. Our in vitro studies suggest that PLCγ-1 plays an important role in invasion of HNSCC cell lines. To explore the biological significance of this finding, we compared protein expression levels of PLCγ-1 in 33 HNSCC tumors and paired normal mucosa harvested several centimeters away from the tumor (see Table 1 for patient cells were fixed, stained, and either counted or photographed using ×400 magnification with an inverted microscope. The experiment was repeated three times with similar results. C, in vitro invasion in presence of PLC and PLCγ-1 inhibition was quantified by counting four fields under ×400 magnification, and the results were plotted as percentage invasion relative to EGF treated control. Bars, ±SE of duplicate wells for each treatment from two independent experiments.
characteristics). Using immunoblotting of tissue lysates, we found a 1.8-fold increase in PLC-γ-1 expression levels in HNSCC tumors compared with levels in paired adjacent normal mucosa (P = 0.0001; Fig. 6). In 30 of 33 (91%) cases, PLC-γ-1 expression levels in the tumor were greater than those in the corresponding normal mucosa. We also examined levels of phosphorylated PLC-γ-1 in a subset of the paired tissues where adequate material was available for analysis (20 subjects). In these samples, activated PLC-γ-1 levels were 1.65-fold higher in HNSCC tumors compared with levels in paired normal mucosa (P = 0.05). These in vitro and in vivo results indicate that EGFR-mediated PLC-γ-1 activation may play an important role in invasion of HNSCC cells.

**DISCUSSION**

In this study we present evidence to support the hypothesis that EGFR mediates invasion of HNSCC cells via activation of PLC-γ-1 and that PLC-γ-1 may be involved in tumor progression. Upon ligand stimulation, EGFR activated PLC-γ-1 in a series of HNSCC cell lines and mediated cellular invasion in vitro. Targeting PLC-γ-1 reduced invasion of HNSCC cells through Matrigel. Furthermore, abrogation of PLC-γ-1 did not modulate proliferation or survival. These findings implicate a specific invasive function of EGFR-mediated signaling via PLC-γ-1 activation. To determine the clinical relevance of our in vitro findings, we examined PLC-γ-1 and phosphorylated PLC-γ-1 levels in HNSCC tumors compared with levels in paired normal adjacent mucosa. This is the first study, to our knowledge, of activated PLC-γ-1 in de novo human cancers. Expression levels of both PLC-γ-1 and phosphorylated PLC-γ-1 were elevated nearly 2-fold in the tumors. These results suggest that PLC-γ-1 plays an important role in EGFR-mediated invasion of HNSCC.

EGFR elicits multiple biological effects in cells overexpressing the receptor including proliferation, prevention of apoptosis, invasion, and transformation (18). Despite the multiplicity of downstream EGFR signaling pathways, several lines of evidence support a redundancy in EGFR signaling. For example, ligand-stimulated EGFR mutants unable to bind SH2 domain proteins use alternate mechanisms including tyrosine-phosphorylated proteins (Shc and Gab1) to activate downstream effectors (19). Thus, an alternate pathway resulting in phenotypic effects expected on EGFR ligand stimulation can overcome the specific inhibition of a downstream effector. However, other studies have reported specificity associated with signaling pathways activated by EGFR. We have shown previously that activation of EGFR stimulates STAT activation pathways that regulate proliferative and antiapoptotic signals (20). Down-modulation of STAT3 using antisense oligonucleotides or dominant-negative approaches resulted in abrogation of growth and apoptosis in HNSCC cells (21). In HNSCC cells, EGFR has been shown to modulate proliferation via MAPK where inhibition of MAPK activation by EGFR did not affect invasion in vitro (8). To elucidate the role of EGFR-mediated signaling via PLC-γ-1 in both mitogenic and motogenic responses, we specifically blocked PLC-γ-1 using several approaches in HNSCC cell lines and determined the effects on proliferation. Our results suggest that PLC-γ-1 inhibition decreases invasion but not proliferation of HNSCC cells in vitro. Similar findings have been reported in prostate carcinoma cells where inhibition of PLC-γ-1 in vitro did not decrease cell growth, whereas in vivo PLC blockade reduced invasion but not tumor volumes (22, 23). Thus, activated EGFR may specifically mediate cancer cell invasion by activation of PLC-γ-1.

This is the first report to demonstrate a correlation between EGFR-mediated PLC-γ-1 signaling in HNSCC and its effects on cellular behavior. Little is known about the biology of invasion in HNSCC cells. Given the high rate of invasion and its associated morbidity and mortality, elucidation of the molecular mechanisms that govern tumor cell invasion is critical for the design of improved therapeutic strategies. To invade, cells secrete proteases that remodel the extracellular matrix and/or activate the tumor cells enabling the cells to migrate although the basement membrane. The MMP family of proteolytic enzymes has been implicated in tumor cell invasion. Several studies have reported up-regulation of MMP-2 and -9 in HNSCC tissues (24–26). Increased expression levels of MMP-9 were found to correlate with overexpression of EGFR in HNSCC tumors (27). Incubation of HNSCC cells with EGFR ligands increased MMP-9 gene expression and in vitro invasion in HNSCC cells (28). The mechanisms that govern EGFR regulation of MMPs are incompletely understood. Another protease linked to increased cell motility, the urokinase-type plasminogen activator, has also been shown to play a role in EGFR-mediated invasion of HNSCC cells (29). However, these proteases appear to function downstream of EGFR activation and are not directly modulated by cytoplasmic EGFR signaling pathways. We found decreased invasion of HNSCC cells after treatment with an EGFR-specific tyrosine kinase inhibitor. Abrogation of HNSCC invasion after EGFR or a PLC-γ-1 inhibition suggests that PLC-γ-1 is activated immediately downstream of EGFR leading to HNSCC cellular invasion.

To examine the clinical relevance of our in vitro data, we measured the levels of PLC-γ-1 and phosphorylated PLC-γ-1 in HNSCC tumors and paired normal mucosa specimens. Our results suggest that HNSCC tumors express significantly higher levels of PLC-γ-1 in tumors compared with adjacent normal epithelial mucosa. Mammary carcinoma cells were reported to express increased levels of EGFR.
EGFR mediates invasion of HNSCC via PLCγ-1 activation

**Fig. 6.** PLCγ-1 levels are increased in HNSCC tumors compared with paired normal tissues. A, immunoblot showing PLCγ-1 levels (top panel), phospho-PLCγ-1 levels (middle panel), and β-actin levels (loading control) in tumor (T) and adjacent normal mucosa (N) from 2 representative HNSCC patients. Densitometric analysis was carried out, and gels were normalized to values of corresponding β-actin levels. Cumulative results showing levels of (B) PLCγ-1 and (C) activated PLCγ-1 in tumors and normal tissue. The levels of PLCγ-1 and phospho-PLCγ-1 in tumor tissues were higher (1.8- and 1.6-fold, respectively) than that in the normal adjacent mucosa (P < 0.0001 and P = 0.05, respectively).

and erbB-2, as well as PLCγ-1 when compared with levels in nonmalignant breast tissue (30). Others have reported in vivo overexpression of PLCγ-1 protein in meningiomas (31) and colorectal carcinomas (32–34). However for the first time, we examined activation status by probing for phosphorylated PLCγ-1 and found it to be increased in the tumor tissues. Up-regulation of PLCγ-1 downstream of EGFR may contribute to the invasive phenotype of HNSCC tumors. Therapies that specifically target PLCγ-1 may reduce local and regional tumor invasion and, hence, improve survival.

**ACKNOWLEDGMENTS**

We thank Lori Miller for technical assistance with cell culture work and Dr. Susanne M. Gollin for providing several HNSCC cell lines.

**REFERENCES**


5635
Epidermal Growth Factor Receptor-stimulated Activation of Phospholipase C \( \gamma \)-1 Promotes Invasion of Head and Neck Squamous Cell Carcinoma

Sufi Mary Thomas, Francesca M. Coppelli, Alan Wells, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/63/17/5629

Cited articles
This article cites 31 articles, 9 of which you can access for free at:
http://cancerres.aacrjournals.org/content/63/17/5629.full#ref-list-1

Citing articles
This article has been cited by 13 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/63/17/5629.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://cancerres.aacrjournals.org/content/63/17/5629.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.